Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 5Prostatic Neoplasms 2Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Multi-centric Castleman's Disease 1Macular dystrophy, corneal type 1 1Lymphoma, Non-Hodgkin 1Lymphoma 1Cytokine Release Syndrome 1

Interventions

Dexamethasone 32Cyclophosphamide 30fludarabine phosphate 25Melphalan 25Busulfan 25Bortezomib 21Tacrolimus 20Lenalidomide 19Peripheral Blood Stem Cell Transplantation 18Mycophenolic Acid 17Whole-Body Irradiation 16Antilymphocyte Serum 16fludarabine 14Calcium Dobesilate 13Thalidomide 12Filgrastim 12Granulocyte Colony-Stimulating Factor 11Methotrexate 10pomalidomide 9Cyclosporine 8Radiotherapy 6Etoposide 6Cord Blood Stem Cell Transplantation 6Surveys and Questionnaires 5Stem Cell Transplantation 5Rituximab 5Methylprednisolone 5sargramostim 4carfilzomib 4Sirolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasms, Plasma Cell × siltuximab × Clear all
NCT01531998 2015-06-19

Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)

M.D. Anderson Cancer Center

Phase 1/2 Completed
14 enrolled 6 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡